National Institute of Infectious Diseases: Results of NIH-Sponsored ACTIV-3 Trial Published
December 23, 2020
December 23, 2020
WASHINGTON, Dec. 23 (TNSJou) -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release:
Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published today in the New England Journal of Medicine. The antibody did not provide clinical benefit compared to placebo. The trial, wh . . .
Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published today in the New England Journal of Medicine. The antibody did not provide clinical benefit compared to placebo. The trial, wh . . .